Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer

Title:Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer

Volume: 28 Issue: 39

Author(s): Mahruba Sultana Niloy, Md. Salman Shakil, Md. Meharab Hassan Alif and Rhonda J. Rosengren*

Affiliation:

• Dept. of Pharmacology and Toxicology, University of Otago, Dunedin,New Zealand

Keywords: KRAS, NSCLC, phytochemicals, cell signaling, cell cycle, and apoptosis.

Abstract: Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity,and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant- based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and downstream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.

Cite this article as:

Niloy Sultana Mahruba , Shakil Salman Md. , Alif Meharab Hassan Md. and Rosengren J. Rhonda *, Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer, Current Medicinal Chemistry 2021; 28 (39) . https://dx.doi.org/10.2174/0929867328666210301105856